Published in Arch Pharm Ber Dtsch Pharm Ges on December 01, 1969
Glycolipid antigen processing for presentation by CD1d molecules. Science (2001) 3.04
Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc Natl Acad Sci U S A (2001) 1.40
Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. Proc Natl Acad Sci U S A (2000) 1.33
Computerized determination of growth kinetic curves and doubling times from cells in microculture. Anal Biochem (1990) 1.13
Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity. J Cancer Res Clin Oncol (1992) 1.11
Human mesenchymal stem cells support megakaryocyte and pro-platelet formation from CD34(+) hematopoietic progenitor cells. J Cell Physiol (2000) 1.08
Dicyclohexylamine effects on HTC cell polyamine content and ornithine decarboxylase activity. Biochim Biophys Acta (1985) 1.05
Kinetics of the alteration and modification of DNA-dependent RNA-polymerase in T4-infected E. coli cells. Eur J Biochem (1969) 1.03
Inhibition of amino acid transport by cis-diamminedichloroplatinum(II) derivatives in L1210 murine leukemia cells. Cancer Res (1983) 0.97
Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment. J Inherit Metab Dis (2006) 0.96
Ornithine decarboxylase modification and polyamine-stimulated enzyme inactivation in HTC cells. Biochem J (1985) 0.90
Putative odour receptors localize in cilia of olfactory receptor cells in rat and mouse: a freeze-substitution ultrastructural study. J Neurocytol (1997) 0.86
Antiestrogens. Synthesis and evaluation of mammary tumor inhibiting activity of 1,1,2,2-tetraalkyl-1,2 -diphenylethanes. J Med Chem (1980) 0.86
[Antimicrobial and tumor-inhibiting properties of dithiourethane and studies on the mechanism of action. 16. Cytostatica]. Pharmazie (1972) 0.85
Transcriptional and post-transcriptional roles of glucocorticoid in the expression of the rat 25,000 molecular weight casein gene. Biochem Biophys Res Commun (1986) 0.85
Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma. J Med Chem (1988) 0.85
An essential role for glucocorticoid in casein gene expression in rat mammary explants. Biochem Biophys Res Commun (1983) 0.85
Hyaluronidase significantly enhances the efficacy of regional vinblastine chemotherapy of malignant melanoma. J Cancer Res Clin Oncol (1995) 0.84
Essential role of insulin in transcription of the rat 25,000 molecular weight casein gene. Science (1984) 0.83
Differential expression of the myocyte enhancer factor 2 family of transcription factors in development: the cardiac factor BBF-1 is an early marker for cardiogenesis. Mol Cell Biol (1994) 0.83
Local and global cerebral blood flow and glucose utilization in the alpha-galactosidase A knockout mouse model of Fabry disease. J Neurochem (2001) 0.82
Platinum compounds with estrogen receptor affinity. Cancer Treat Rev (1990) 0.81
1,1,2-triphenylbut-1-enes: relationship between structure, estradiol receptor affinity, and mammary tumor inhibiting properties. J Med Chem (1982) 0.80
Investigations on the antiproliferative effects of amino acid antagonists targeting for aminoacyl-tRNA synthetases. Part II--The antileukemic effect. Arch Pharm (Weinheim) (1989) 0.79
[The mode of local anesthetic action of cinchocaine homologues]. Arzneimittelforschung (1970) 0.78
Dichloro-[1-(hydroxyphenyl)-2-phenylethylenediamine]platinum(II) complexes: testing on the human ovarian cancer cell lines NIH: OVCAR3 and SK OV 3. Arch Pharm (Weinheim) (1992) 0.78
A rapid luciferase transfection assay for transcription activation effects and stability control of estrogenic drugs in cell cultures. J Cancer Res Clin Oncol (1994) 0.78
Different response of murine and human mammary tumour models to a series of diastereoisomeric [1,2-bis(difluorophenyl) ethylenediamine]dichloroplatinum(II) complexes. J Cancer Res Clin Oncol (1991) 0.78
[Synthesis of 14C-anpirtoline]. Arch Pharm (Weinheim) (1988) 0.78
Dissociation of estrogenic and cytotoxic properties of an estrogen receptor-binding platinum complex in human breast cancer cell lines. Cancer Res (1991) 0.77
Benzylamines: synthesis and evaluation of antimycobacterial properties. J Med Chem (1984) 0.77
Investigations on the antiproliferative effects of amino acid antagonists targeting for aminoacyl-tRNA synthetases. Part I--The antibacterial effect. Arch Pharm (Weinheim) (1989) 0.77
Correction to erythromycin ototoxicity. Drug Intell Clin Pharm (1981) 0.77
[meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II), a new drug not only parenterally but also orally active in the therapy of breast and prostate cancer. J Cancer Res Clin Oncol (1993) 0.77
Mammary tumor inhibiting [1,2-bis(2,6-dihalo-3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, III: Relationship between structure and estrogenic activity of the diamine ligands, their sulfatoplatinum(II) and diiodoplatinum(II) complexes. Arch Pharm (Weinheim) (1993) 0.76
[1,2-Bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloro-platinum(II): an endocrine-active platinum complex with a specific prostatic tumor-inhibiting activity. Prostate (1989) 0.76
Chemosensitivity of human MCF-7 breast cancer cells to diastereoisomeric diaqua(1,2-diphenylethylenediamine) platinum(II) sulfates and specific platinum accumulation. Cancer Chemother Pharmacol (1992) 0.76
Multiple CCAAT binding proteins regulate the expression of the angiotensinogen gene. Cell Mol Biol Res (1993) 0.76
Computer modelling of estrogenic transcriptional activation can account for different types of dose-response curves of estrogens. J Steroid Biochem Mol Biol (1993) 0.76
Stability and cellular studies of [rac-1,2-bis(4-fluorophenyl)-ethylenediamine][cyclobutane-1,1- dicarboxylato]platinum(II), a novel, highly active carboplatin derivative. J Cancer Res Clin Oncol (1998) 0.76
N,N'-Dialkyl-1,2-bis(hydroxyphenyl)ethylenediamines and N,N-dialkyl-4,5-bis(4-hydroxyphenyl)imidazolidines: syntheses and evaluation of their mammary tumor inhibiting activity. J Med Chem (1982) 0.76
[Development of new antiestrogens of the 3,3'-dihydroxy-alpha, beta-diethylstilbene-type and their evaluation on the DMBA-induced hormone dependent mammary carcinoma of the SD-rat (author's transl)]. J Cancer Res Clin Oncol (1980) 0.76
Development of a parenterally administrable hydrosol preparation of the "third generation platinum complex" [(+/-)-1,2-bis(4-fluorophenyl)ethylenediamine]dichloroplatinum(II). Part 1. Preparation and studies on the stability and antitumor activity. Arch Pharm (Weinheim) (1995) 0.75
Effects of estrogen-depletion on rat casein gene expression. Biochem Biophys Res Commun (1984) 0.75
Dichloro[1,2-bis(4-hydroxyphenyl)ethylenediamine]platinum(II) complexes: an approach to develop compounds with a specific effect on the hormone-dependent mammary carcinoma. J Med Chem (1984) 0.75
Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl) ethylenediamine]dichloroplatinum(II)-complexes, Part II: Biological properties. Arch Pharm (Weinheim) (1989) 0.75
[Antitumor activity of cis-dichloro-bis-(alpha-amino acid ester)platinum complexes]. Arch Pharm (Weinheim) (1983) 0.75
A simple method of delayed processing of tumor tissue in a soft agar clonogenic assay. J Cancer Res Clin Oncol (1988) 0.75
[Synthesis and tumor inhibiting effect of N-(bis(2-chlorethyl)-aminomethyl)-amides. 21. Cytostatic agents]. Arch Pharm (Weinheim) (1973) 0.75
Ring-substituted 1,2-dialkylated 1,2-bis(hydroxyphenyl)ethanes. 2. Synthesis and estrogen receptor binding affinity of 4,4'-, 5,5'-, and 6,6'-disubstituted metahexestrols. J Med Chem (1984) 0.75
[Pharmacology of potential antidepressants of the N-L-phenylalanyl-beta-phenylalkylamine class]. Arzneimittelforschung (1983) 0.75
[Experimental chemotherapy of mammary neoplasms. A review]. Pharmazie (1976) 0.75
Ring-substituted 1,2-dialkylated 1,2-bis(hydroxyphenyl)ethanes. 1. Synthesis and estrogen receptor binding affinity of 2,2'- and 3,3'-disubstituted hexestrols. J Med Chem (1983) 0.75
[The relationship between structure and tuberculostatic effect in the benzylamine group]. Pharmazie (1976) 0.75
[Cis-dichloro(bis(oligopeptide ester))platinum (II) complexes: studies on the demonstration of their antitumor action with a bacteriological test system]. Arch Pharm (Weinheim) (1984) 0.75
3,4-bis(3'-hydroxyphenyl)hexane--a new mammary tumor-inhibiting compound. J Cancer Res Clin Oncol (1982) 0.75
N,N'-Dialkylbis(dichlorophenyl)ethylenediamines and -imidazolidines: relationship between structure and estradiol receptor affinity. J Med Chem (1980) 0.75
[Intraocular lenses - aphorisms of an operating practitioner (author's transl)]. Klin Monbl Augenheilkd (1979) 0.75
[The mode of action of antimycobacterial benzylamines]. Arch Pharm (Weinheim) (1989) 0.75
[The action mechanisms of local anesthetics. 9. N-aminoacyl-beta-phenylalkylamine tested for development of antidepressive agents from psychotonics]. Pharmazie (1976) 0.75
Cytotoxic ester derivatives of the mammary tumor inhibiting antiestrogen 2,3-bis(2-fluoro-4-hydroxyphenyl)-2,3-dimethylbutane. Arch Pharm (Weinheim) (1990) 0.75
[Activity of cis-bis(glycylglycine ethyl ester)platinum(II) chloride-effects on nucleic acid metabolism]. Arch Pharm (Weinheim) (1983) 0.75
Ester derivatives of the mammary-tumor-inhibiting antiestrogen 2,3-bis(2-fluoro-4-hydroxyphenyl)-2,3-dimethylbutane. J Cancer Res Clin Oncol (1989) 0.75
Carrier mediated action of platinum complexes on estrogen receptor positive tumors. Eur J Cancer Clin Oncol (1989) 0.75
The tumor-inhibiting effect of diethylstilbestrol-3,4-oxide. J Cancer Res Clin Oncol (1981) 0.75
Rationale for combining tamoxifen and interferon in the treatment of advanced breast cancer. J Cancer Res Clin Oncol (1989) 0.75
[Antiestrogenic N-(4-hydroxyphenyl)-n-(1,1,1,-trifluoro-2-propyl)-4- hydroxybenzamides: influence of hydrophobic groups substituted in the ortho-position of the benzamide-fragment on activity]. Arch Pharm (Weinheim) (1990) 0.75
Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]dichloroplatinum(II)-compl exe s, Part I: Synthesis. Arch Pharm (Weinheim) (1989) 0.75
Acetoxy-substituted 1,1,2-triphenylbut-1-enes with antiestrogenic and mammary tumor inhibiting properties. J Med Chem (1985) 0.75
Mammary tumor inhibiting properties of the (S,S)-configurated [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complex. Arch Pharm (Weinheim) (1990) 0.75
[14C-labeling of D 16,427, a new positive inotropic agent]. Arch Pharm (Weinheim) (1986) 0.75
Anticancer drugs: estrophilic cisplatin derivatives. Cancer Treat Rev (1987) 0.75
[Antineoplastic effect of N,N',N''-trihydroxymethylmelamine and analogous compounds. 23. Cytostatic agents]. Arch Pharm (Weinheim) (1973) 0.75
[Synthesis and pharmacological test of N-(3'-methoxy-benzamidomethyl)-D-norephedrine and Analogous Compounds (author's transl)]. Arch Pharm (Weinheim) (1976) 0.75
Synthesis and evaluation of catechol analogs of diethylstilbestrol on a hormone-dependent human mammary carcinoma implanted in nude mice. J Cancer Res Clin Oncol (1982) 0.75
[The effect of the culture medium on the testing of antimycobacterial compounds]. Arch Pharm (Weinheim) (1989) 0.75
[Antimycobacterial effect of N-alkylbenzylamines]. Pharmazie (1977) 0.75
Influence of alkyl-chain fluorination on the action of mammary tumor inhibiting 2,3-bis(hydroxyphenyl)butanes and 2,3-bis(hydroxyphenyl)but-2-enes. J Med Chem (1986) 0.75
The tumor-inhibiting effect of isomeric dichloro(diphenylethylenediamine)platinum(II) complexes. J Cancer Res Clin Oncol (1984) 0.75
Mammary tumor inhibiting effect of 3,3'-diacetoxy-alpha, beta-dialkylstilbenes and of related stilbene oxides. J Med Chem (1982) 0.75
[The working mechanism of local anesthetics. 8. Preparation of enantiomer N-phthalylamino carbonic acids]. Pharmazie (1976) 0.75
[Mammary-tumor-inhibiting antiestrogens of the 3,3'-dihydroxy-alpha, beta-dialkylstilbene type (author's transl)]. Arch Pharm (Weinheim) (1980) 0.75
Potential antiestrogens. Synthesis and evaluation of mammary tumor inhibiting activity of 1,2-dialkyl-1,2-bis(3'-hydroxyphenyl)ethanes. J Med Chem (1981) 0.75
[Syntheses and evaluation of the potentially oestrophilic cytostatics 2,3-epoxy-3,4-bis-(4-acetoyphenyl)-4-hexene and 2,3,4,5-bisepoxy-3,4-bis-(4-acetoxyphenyl)hexane (author's transl)]. Arch Pharm (Weinheim) (1982) 0.75
[Azomethines and oxazolidines from norfenefrine. Development of compounds with prolonged action and blood pressure increasing effect]. Arch Pharm (Weinheim) (1975) 0.75
[Mechanism of action of cis-bis(glycylglycine ethyl ester)platinum(II) chloride--effect on protein biosynthesis]. Arch Pharm (Weinheim) (1983) 0.75
Influence of ring substituents on the antitumor effect of dichloro(1,2-diphenylethylenediamine)platinum(II) complexes. J Cancer Res Clin Oncol (1988) 0.75
Development of selectively acting platinum complexes. Cancer Treat Rev (1984) 0.75
[The antineoplastic action of o-substituted [1,2-bis(4-hydroxyphenyl)-ethylenediamine]dichloroplatinum (II) complexes and their methylethers]. Arch Pharm (Weinheim) (1988) 0.75
[Studies on the mammary tumor inhibiting effect of cis-dichlorobis(glycylglycinethylester)platinum(II) (author's transl)]. Arch Pharm (Weinheim) (1981) 0.75
Effect of estrophilic platinum complex on the mouse uterus. Virchows Arch B Cell Pathol Incl Mol Pathol (1987) 0.75
3,4-bis(3'-hydroxyphenyl)hexane--a new mammary tumor-inhibiting compound. Studies on the mechanism of action on the DMBA-induced, hormone-dependent mammary tumor of the rat. J Cancer Res Clin Oncol (1982) 0.75
Design of metallocenic drugs. IARC Sci Publ (1986) 0.75
[Antimycobacterial N-alkylbenzylamines: synthesis and testing of 4-aminomethyl-2-hydroxybenzoic acid and its homologs]. Arch Pharm (Weinheim) (1982) 0.75
[N-(4-hydroxyphenyl)-N-(1,1,1-trifluor-2-propyl)-4-hydroxyben zamide: synthesis and pharmacologic evaluation of a new antiestrogen]. Arch Pharm (Weinheim) (1988) 0.75
[Investigations of pharmacokinetics and metabolic behavior of N-L-pnenylalanyl-L-2-amino-1-phenylpropane (author's transl)]. Arzneimittelforschung (1981) 0.75
[The mode of action of local anesthetics. 7. Synthesis of enantiomeric N-aminoacyl-2.6.-dimethylaniline, -benzylamine and-2-phenylethylamine]. Pharmazie (1976) 0.75
[Relations between structure and antitumor activity of cis-dichloro[bis(oligopeptide-ester)]platinum(II) complexes]. Arch Pharm (Weinheim) (1983) 0.75